Enovis (NYSE:ENOV – Get Rating) is one of 48 publicly-traded companies in the “Surgical appliances & supplies” industry, but how does it weigh in compared to its rivals? We will compare Enovis to related companies based on the strength of its institutional ownership, valuation, analyst recommendations, profitability, earnings, risk and dividends.
Insider and Institutional Ownership
50.9% of shares of all “Surgical appliances & supplies” companies are owned by institutional investors. 8.2% of Enovis shares are owned by insiders. Comparatively, 10.9% of shares of all “Surgical appliances & supplies” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares Enovis and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Enovis||$3.85 billion||$71.66 million||50.13|
|Enovis Competitors||$1.29 billion||$145.58 million||34.47|
Enovis has higher revenue, but lower earnings than its rivals. Enovis is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Volatility & Risk
Enovis has a beta of 2.2, indicating that its stock price is 120% more volatile than the S&P 500. Comparatively, Enovis’ rivals have a beta of 0.81, indicating that their average stock price is 19% less volatile than the S&P 500.
This table compares Enovis and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and price targets for Enovis and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Enovis presently has a consensus price target of $73.00, indicating a potential upside of 10.32%. As a group, “Surgical appliances & supplies” companies have a potential upside of 62.26%. Given Enovis’ rivals higher possible upside, analysts plainly believe Enovis has less favorable growth aspects than its rivals.
Enovis beats its rivals on 6 of the 10 factors compared.
Enovis Company Profile (Get Rating)
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries. It offers rigid and soft orthopedic bracings, hot and cold therapy products, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management, and physical therapy products; and a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis Corporation sells its products through independent distributors, such as healthcare professionals, consumer retail stores, and pharmacies; and directly under the DJO brand. The company was formerly known as Colfax Corporation. Enovis Corporation is headquartered in Wilmington, Delaware.
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.